Chronic Kidney Disease

For patients with type 2 diabetes and obesity, undergoing Roux-en-Y gastric bypass surgery led to greater remission rates of albuminuria and early stage chronic kidney disease compared with best medical care.

For patients with kidney disease not yet on dialysis, omega-3 fatty acid supplementation led to improvements in pulse wave velocity and serum triglyceride levels, suggesting that daily use could reduce risk for cardiovascular events.

U.S. News & World Report has released the 31st edition of its “Best Hospitals” rankings, which includes the best hospitals for nephrology. For 2020 to 2021, the Mayo Clinic again ranked number one.

Ferric citrate may be more effective than ferrous sulfate for treating iron deficiency in patients with chronic kidney disease, according to this study.

For patients with chronic kidney disease or on dialysis, plant-based diets have been viewed as second rate to animal protein. It was believed that plant-based diets would cause phosphorus and potassium levels to rise and plant proteins could not meet the needs of the patient with kidney disease.

A lack of EULAR/European Renal Association-European Dialysis and Transplant Association response at 1 year among patients with lupus nephritis predicted chronic kidney disease, researchers reported.

A review of published studies revealed hip and nonvertebral fracture risks increased for patients with chronic kidney disease stages G3a-G5D, leading researchers to suggest CKD be considered as an additional risk factor for fractures.

Results of a prospective, observational study showed that patients with chronic kidney disease and type 2 diabetes experienced frequent hypoglycemic episodes, many of which were deemed prolonged and severe.

Topline findings from the FIDELIO-DKD study show the investigational drug finerenone delayed the progression of chronic kidney disease and reduced risk for cardiovascular events among adults with type 2 diabetes compared with placebo.

An analysis of published studies showed relief of fatigue for patients with chronic kidney disease and anemia when treatment with erythropoietin stimulating agents led to hemoglobin levels higher than currently recommended targets.